Pharmaceutical News

RSS

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.

14 Sep 2009

FAB Pharma to develop new class of anti-MRSA drugs

FAB Pharma today announced the completion of a €2.3 million round of series A funding led by CDC innovation and co-led by Bioam Gestion.

14 Sep 2009

Marketing study conducted to investigate decline in Gardasil vaccine supply

Sales of Merck's HPV vaccine, Gardasil, declined by a third this year, and three years after the FDA approved the drug an estimated three out of four women remain unvaccinated -- despite millions spent on advertising and lobbying for government mandates. A recent marketing study offers a reason.

14 Sep 2009

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

11 Sep 2009

IRIN examines report on varying cost of ARVs for countries with similar socioeconomic status

IRIN examines a recent report (.pdf) that found varying price rates countries pay for antiretrovirals (ARVs) - with "some nations … paying up to three times more for the life-prolonging medicines than others with similar HIV prevalence and income levels."

11 Sep 2009

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

11 Sep 2009

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

The American Lung Association is making it easier for people to get their seasonal flu vaccine this year with the availability of its 2009-2010 Flu Clinic Locator. The largest online directory of public seasonal influenza vaccination clinics is now available at www.flucliniclocator.org.

11 Sep 2009

Bioneutral's broad spectrum antimicrobial eradicates the H1N1 swine flu virus

BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia, demonstrated that Ygiene® antimicrobial diluted 1 to 10 with water can totally eradicated the H1N1 Swine Flu virus in 59 seconds on an unclean, soiled surface.

11 Sep 2009

Federal court's approval clears the way for pricing rollback of pharmaceutical drugs

Purchasers of pharmaceutical drugs including consumers and health plans will soon enjoy a rollback of benchmark prices of some of the most common prescription medications after a Federal Appeals Court last week affirmed the approval of a settlement with two leading drug-pricing publishers, First DataBank, Inc. and Medi-Span, a division of Wolters Kluwer Health, Inc.

11 Sep 2009

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced today that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.

11 Sep 2009

YuYeQingHuo OTC capsules to treat throat inflammation launched by American Oriental Bioengineering

American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that the Company has launched a new product called YuYeQingHuo Capsules ("YYQH").

11 Sep 2009

Accupac to manufacture Access Pharmaceuticals' MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

11 Sep 2009

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.

11 Sep 2009

Results from a preclinical study of Variation's influenza vaccine to be presented at ICAAC meeting

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today announced that it plans to present positive results from a preclinical study of the company’s proprietary influenza vaccine at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held at the Moscone Convention Center in San Francisco, California.

11 Sep 2009

U.S. Secretary Kathleen Sebelius to participate in a vaccination exercise on the anniversary of 9/11

On the anniversary of 9/11, U.S. Secretary of Health and Human Services Kathleen Sebelius and Assistant Secretary for Health Howard Koh will honor the members of the Medical Reserve Corps and participate in a vaccination exercise in Alexandria, Va., on Friday, September 11, 2009.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

PCMA stresses on improving affordability in the health care system

“Pharmacy benefit managers (PBMs) share the President’s goal of improving affordability as a central tenant to reforming the health care system. Tools pioneered by PBMs – including those which increase the use of generic medicines – have accomplished this goal by lowering costs and expanding access to prescription drugs for consumers and payers.

11 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

11 Sep 2009

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.

11 Sep 2009

Pharmaceutical News

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

FAB Pharma to develop new class of anti-MRSA drugs

Marketing study conducted to investigate decline in Gardasil vaccine supply

Signum Biosciences awarded $1.6 million SBIR Phase II grant

IRIN examines report on varying cost of ARVs for countries with similar socioeconomic status

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

Bioneutral's broad spectrum antimicrobial eradicates the H1N1 swine flu virus

Federal court's approval clears the way for pricing rollback of pharmaceutical drugs

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

YuYeQingHuo OTC capsules to treat throat inflammation launched by American Oriental Bioengineering

Accupac to manufacture Access Pharmaceuticals' MuGard

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

Results from a preclinical study of Variation's influenza vaccine to be presented at ICAAC meeting

U.S. Secretary Kathleen Sebelius to participate in a vaccination exercise on the anniversary of 9/11

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

PCMA stresses on improving affordability in the health care system

Cymbalta maintains reduction in pain for patients with chronic low back pain

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News